59 Results
Sort By:
Published on October 18, 2023
Precision medicines are gaining increasing traction in healthcare. Here are five companies driving the field with recent approvals in RNA therapeutics, cell and gene therapies, and more. Medicines have traditionally been given to patients in a one-size-fits-all approach, with many patients failing to benefit and experiencing side effects. This challenge…
Published on August 9, 2023
In 2012, 6-year-old Emily Whitehead’s acute lymphoblastic leukemia returned, and no traditional treatment options remained. So she became the first child to receive CAR-T immunotherapy, which engineered her T cells to fight the cancer. More than a decade later, Emily is cancer-free. Her success spawned new hope that immunotherapy could…
Published on August 9, 2023
Depending on which research report is referenced, there are anywhere from a couple hundred to more than 600 bispecific antibodies (bsAbs) in preclinical and clinical development by pharma and biotech companies around the world. Nine of the 12 bsAbs that have received approval globally target cancer. But after the first…
Published on June 5, 2023
Chimeric antigen receptor T cell therapy, commonly referred to as CAR T therapy, is an intervention that uses a patient’s own cells to fight their cancer. The therapy first received US Food and Drug Administration (FDA) approval in 2017. For some patients, this meant long term remission and even cures…
Published on June 5, 2023
A little over a decade ago, a paper was published in Science1 that made science fiction a reality. Emmanuel Charpentier, Jennifer Doudna, and colleagues reported that they had identified a means of harnessing an element of a bacterial immune system to carry out genome editing in a way that was…
Published on March 29, 2023
Key biologic features of tumor progression are influenced by the circadian rhythm, which could be used to optimize timing of drug delivery and maximize safety and efficacy, suggests a review carried out by researchers in Switzerland. “The circadian rhythm governs most of the cellular functions implicated in cancer progression, and…
Published on February 10, 2023
The role that real-world evidence, and the data that feeds into it, play in the clinical trials arena is changing. For many years, drug developers and regulators have collected real-world data (RWD) on adverse events linked to newly approved medicines. However, this data has not played a significant role in…
Published on December 21, 2022
Researchers at the Cancer Research UK Cambridge Institute at the University of Cambridge report that using mouse models they have developed a new technique for identifying the different types of cells in a tumor. The method allows tracking of tumor cells during treatment, to observe which types of cells die…
Published on April 13, 2022
Leukemia Non-Responders to CAR-T Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results from researchers at the National Cancer Institute (NCI) “We identified a signature of nonresponse that is…
Published on October 7, 2021
A collaboration between the Koch Institute and Dana-Farber Precision Medicine Programs has that subtle changes in cell mass can be used as a functional biomarkers of patients’ responses to cancer treatments. The retrospective study, published recently in Cell Reports, shows the diagnostic test based on a “functional precision medicine” approach…
Published on July 27, 2021
Chemotherapy has helped make Acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, an international team of researchers have demonstrated how a class of chemotherapy drugs called thiopurines can lead to mutations that set up patients for relapse. Their findings were published in the journal Nature Cancer in a…
Published on May 20, 2021
An ongoing study shows that combining ponatinib and blinatumomab provides remarkable complete responses in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Both are usually treated with tyrosine kinase inhibitors (TKI) and systemic chemotherapy, often with the addition of an…
Published on January 7, 2021
Scientists led by teams at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches that can regulate the activity of chimeric antigen receptor (CAR) T cells, a form of cell-based immunotherapy that has demonstrated dramatic success in treating some advanced cancers, but which poses a significant…
Published on July 24, 2020
Content sponsored by As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients. The development of chimeric antigen receptor T cell (CAR-T cell) therapies—such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)—and their success in…
Published on July 6, 2020
Gene coding regions constitute 2% of the human genome. St. Jude Children’s Research Hospital scientists have developed a computational tool to identify alterations that drive tumor formation in the remaining 98% of the genome. The method will aid discovery of oncogenes and advances in precision medicine for children and adults…